Ross Eberly

Cooley advised a syndicate of globally recognized private and public investors in connection with the management-led majority stake acquisition of HistoSonics, the developer of the Edison Histotripsy System and novel histotripsy therapy platform, valuing the company at approximately $2.25 billion.

Cooley advised Inmagene Biopharmaceuticals, a privately held, global clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, on its definitive merger agreement with Ikena Oncology (Nasdaq: IKNA).

Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie.

Cooley advised SoftEye, a San Diego-based company developing specialized chips, cameras, software and algorithms for use in smart glasses, on its sale to TDK Corporation, a Tokyo-based global leader in advanced electronic solutions designed for a smarter, more connected world.

Cooley advised Heliogen, a provider of on-demand clean energy technology solutions, on its definitive agreement with Zeo Energy, a Florida-based provider of residential solar and energy efficiency solutions, representing the culmination of Heliogen’s review of strategic alternatives and pursuant to which Zeo will acquire all of Heliogen’s outstanding equity securities in an all-stock transaction.